These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. VE-cadherin increases the half-life of VEGF receptor 2. Calera MR; Venkatakrishnan A; Kazlauskas A Exp Cell Res; 2004 Oct; 300(1):248-56. PubMed ID: 15383331 [TBL] [Abstract][Full Text] [Related]
10. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability. Liao F; Doody JF; Overholser J; Finnerty B; Bassi R; Wu Y; Dejana E; Kussie P; Bohlen P; Hicklin DJ Cancer Res; 2002 May; 62(9):2567-75. PubMed ID: 11980651 [TBL] [Abstract][Full Text] [Related]
11. Cdc42 regulates adherens junction stability and endothelial permeability by inducing alpha-catenin interaction with the vascular endothelial cadherin complex. Broman MT; Kouklis P; Gao X; Ramchandran R; Neamu RF; Minshall RD; Malik AB Circ Res; 2006 Jan; 98(1):73-80. PubMed ID: 16322481 [TBL] [Abstract][Full Text] [Related]
12. The tumour necrosis factor-alpha induced vascular permeability is associated with a reduction of VE-cadherin expression. Hofmann S; Grasberger H; Jung P; Bidlingmaier M; Vlotides J; Janssen OE; Landgraf R Eur J Med Res; 2002 Apr; 7(4):171-6. PubMed ID: 12010652 [TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor beta signaling. Labelle M; Schnittler HJ; Aust DE; Friedrich K; Baretton G; Vestweber D; Breier G Cancer Res; 2008 Mar; 68(5):1388-97. PubMed ID: 18316602 [TBL] [Abstract][Full Text] [Related]
14. Partial loss of VE-cadherin improves long-term outcome and cerebral blood flow after transient brain ischemia in mice. Gertz K; Kronenberg G; Uhlemann R; Prinz V; Marquina R; Corada M; Dejana E; Endres M BMC Neurol; 2016 Aug; 16(1):144. PubMed ID: 27538712 [TBL] [Abstract][Full Text] [Related]
15. Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site. Wallez Y; Cand F; Cruzalegui F; Wernstedt C; Souchelnytskyi S; Vilgrain I; Huber P Oncogene; 2007 Feb; 26(7):1067-77. PubMed ID: 16909109 [TBL] [Abstract][Full Text] [Related]
16. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Gutierrez LS; Schulman A; Brito-Robinson T; Noria F; Ploplis VA; Castellino FJ Cancer Res; 2000 Oct; 60(20):5839-47. PubMed ID: 11059781 [TBL] [Abstract][Full Text] [Related]
17. Targeted null-mutation in the vascular endothelial-cadherin gene impairs the organization of vascular-like structures in embryoid bodies. Vittet D; Buchou T; Schweitzer A; Dejana E; Huber P Proc Natl Acad Sci U S A; 1997 Jun; 94(12):6273-8. PubMed ID: 9177207 [TBL] [Abstract][Full Text] [Related]
18. Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Navaratna D; McGuire PG; Menicucci G; Das A Diabetes; 2007 Sep; 56(9):2380-7. PubMed ID: 17536065 [TBL] [Abstract][Full Text] [Related]
19. Regulation of VE-cadherin linkage to the cytoskeleton in endothelial cells exposed to fluid shear stress. Ukropec JA; Hollinger MK; Woolkalis MJ Exp Cell Res; 2002 Feb; 273(2):240-7. PubMed ID: 11822879 [TBL] [Abstract][Full Text] [Related]
20. IQGAP1 mediates VE-cadherin-based cell-cell contacts and VEGF signaling at adherence junctions linked to angiogenesis. Yamaoka-Tojo M; Tojo T; Kim HW; Hilenski L; Patrushev NA; Zhang L; Fukai T; Ushio-Fukai M Arterioscler Thromb Vasc Biol; 2006 Sep; 26(9):1991-7. PubMed ID: 16763158 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]